Other content in this Stream
From enabling the manufacturing of biopharmaceuticals to developing its own drug pipeline.
Prometic Life Sciences Inc. Conference Call to Discuss interim CEO and Strategy Update December 19 2018
Prof. Simon Best appointed interim CEO of Prometic Life Sciences
Prometic to initiate PBI-4050 pivotal phase 3 clinical trial in Alström Syndrome
Annual Information Form 2017
Prometic Annual Information Form 2017
Quarterly Report Q2 2018
Quarterly Report Q1 2018
Prometic reports its 2018 first quarter highlights and financial results
Corporate Governance and Nominating Committee Charter 2017
Board of Directors Charter 2017
Audit, Risk and Finance Committee Charter 2017
Code of Ethics and Business Conduct 2017
Full detailed breakdown of Prometics Code of Ethics and Business Conduct for 2017 including details on regulatory compliance.
Virtual Tour of Prometic Life Science's Manufacturing Process
Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency
At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD).
Joe Parker, MD: PBI-4050 Demonstrates Promising Efficacy Results for IPF Treatment